Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Pharmaceutical industry · Shenzhen, Guangdong
About Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. is a Chinese biopharmaceutical company founded in 1998 in Shenzhen, Guangdong Province, with a dual A+H listing (Shenzhen 002399 and Hong Kong 9989). Its official website presents it as a global company driven by unmet clinical needs, with business covering more than 50 countries and regions.
Its core business is the full heparin industrial chain: it is one of the world's large suppliers of heparin sodium API and enoxaparin sodium API, and it markets enoxaparin injections under brands such as Inhixa, Neoparin and Prolongin through its Techdow network in Europe and the United States. It also supplies pancreatin API.
The group rounds out its offer with CDMO services for recombinant large molecules and gene therapy products — through Cytovance Biologics in the United States and Scientific Protein Laboratories, a heparin specialist — and with an innovative-drugs business covering investment, development and commercialisation. For buyers of anticoagulant active ingredients, Hepalink is one of China's world-reference suppliers.
Its core business is the full heparin industrial chain: it is one of the world's large suppliers of heparin sodium API and enoxaparin sodium API, and it markets enoxaparin injections under brands such as Inhixa, Neoparin and Prolongin through its Techdow network in Europe and the United States. It also supplies pancreatin API.
The group rounds out its offer with CDMO services for recombinant large molecules and gene therapy products — through Cytovance Biologics in the United States and Scientific Protein Laboratories, a heparin specialist — and with an innovative-drugs business covering investment, development and commercialisation. For buyers of anticoagulant active ingredients, Hepalink is one of China's world-reference suppliers.